A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

Summary

This study is designed to study the pharmacokinetic (PK) and safety profiles of a single dose of efimosfermin alfa in participants with varying degrees of Hepatic Impairment (HI) (assessed by Child-Pugh score) due to steatotic liver disease, with and without significant alcohol consumption.

Timeline

Start

2026-03-13

Primary completion

2027-10-13

Completion

2027-10-13

Drugs

Indications